319 related articles for article (PubMed ID: 32641413)
1. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
3. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
5. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
6.
Longerich T; Endris V; Neumann O; Rempel E; Kirchner M; Abadi Z; Uhrig S; Kriegsmann M; Weiss KH; Breuhahn K; Mehrabi A; Weber TF; Wilkens L; Straub BK; Rosenwald A; Schulze F; Brors B; Froehling S; Pellegrino R; Budczies J; Schirmacher P; Stenzinger A
Gut; 2019 Jul; 68(7):1287-1296. PubMed ID: 30901310
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
8. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
10. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
11. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.
Ueda Y; Hiyama E; Kamimatsuse A; Kamei N; Ogura K; Sueda T
J Pediatr Surg; 2011 Dec; 46(12):2221-7. PubMed ID: 22152854
[TBL] [Abstract][Full Text] [Related]
12. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma.
Takagi H; Sasaki S; Suzuki H; Toyota M; Maruyama R; Nojima M; Yamamoto H; Omata M; Tokino T; Imai K; Shinomura Y
J Gastroenterol; 2008; 43(5):378-89. PubMed ID: 18592156
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
14. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
[TBL] [Abstract][Full Text] [Related]
15. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
16. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.
Kaur P; Mani S; Cros MP; Scoazec JY; Chemin I; Hainaut P; Herceg Z
Tumour Biol; 2012 Apr; 33(2):325-36. PubMed ID: 22351518
[TBL] [Abstract][Full Text] [Related]
18. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
